Ryvu Therapeutics got full approval to conduct Phase I/II study of RVU120 (SEL120) in patients with relapsed/refractory metastatic or advanced solid tumors in Poland
- Friday, May 28, 2021, 7:14
- Environment
- Add a comment
KRAKOW, Poland, May 28, 2021 /PRNewswire/ — Ryvu Therapeutics (WSE: RVU), a clinical stage drug discovery and development company focusing on novel small molecule therapies that address emerging targets in oncology, announced today that its Clinical Trial Application (CTA) to commence a…
About the Author
adminasapcorp has written 39256 stories on this site.